Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Y Yu

Showing results (11-20 of 234) with videos related to

Pageof 24
Sort By:
Therapeutic Advances in Medical Oncology|September 2, 2016
Targeting intratumoral androgens: statins and beyondMichael T Schweizer, Evan Y Yu
Immunotherapy|October 4, 2017
Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?Jorge D Ramos, Evan Y Yu
Current Oncology Reports|April 2, 2003
Neoadjuvant therapy for high-risk localized prostate cancerEvan Y Yu, William K Oh
The Journal of Urology|February 11, 2017
Re: Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy: W. C. Duivenvoorden, S. Daneshmand, D. Canter, Y. Lotan, P. C. Black, H. Abdi, B. W. van Rhijn, E. E. Fransen van de Putte, P. Zareba, I. Koskinen, W. Kassouf, S. L. Traboulsi, J. E. Kukreja, P. J. Boström, B. Shayegan and J. H. Pinthus J Urol 2016;196:1627-1633Jorge D Ramos, Evan Y Yu
JAMA Oncology|November 5, 2016
Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of ChemotherapyEvan Y Yu, Daniel W Lin
Future Oncology (London, England)|August 25, 2022
Enfortumab vedotin in the treatment of urothelial cancers and beyondRisa L Wong, Evan Y Yu
Cancer Treatment and Research|October 8, 2005
The origin of cancerEvan Y Yu, William C Hahn
Cancers|January 14, 2017
AR-Signaling in Human Malignancies: Prostate Cancer and BeyondMichael T Schweizer, Evan Y Yu
Expert Review of Molecular Diagnostics|September 26, 2007
Positron emission tomography imaging as a cancer biomarkerEvan Y Yu, David A Mankoff
Urologic Oncology|November 13, 2016
Making urothelial carcinomas less immune to immunotherapyJorge D Ramos, Evan Y Yu
Pageof 24

Showing results (11-20 of 234) with videos related to

Sort By:
Pageof 24
Therapeutic Advances in Medical Oncology|September 2, 2016
Targeting intratumoral androgens: statins and beyondMichael T Schweizer, Evan Y Yu
Immunotherapy|October 4, 2017
Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?Jorge D Ramos, Evan Y Yu
Current Oncology Reports|April 2, 2003
Neoadjuvant therapy for high-risk localized prostate cancerEvan Y Yu, William K Oh
The Journal of Urology|February 11, 2017
Re: Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy: W. C. Duivenvoorden, S. Daneshmand, D. Canter, Y. Lotan, P. C. Black, H. Abdi, B. W. van Rhijn, E. E. Fransen van de Putte, P. Zareba, I. Koskinen, W. Kassouf, S. L. Traboulsi, J. E. Kukreja, P. J. Boström, B. Shayegan and J. H. Pinthus J Urol 2016;196:1627-1633Jorge D Ramos, Evan Y Yu
JAMA Oncology|November 5, 2016
Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of ChemotherapyEvan Y Yu, Daniel W Lin
Future Oncology (London, England)|August 25, 2022
Enfortumab vedotin in the treatment of urothelial cancers and beyondRisa L Wong, Evan Y Yu
Cancer Treatment and Research|October 8, 2005
The origin of cancerEvan Y Yu, William C Hahn
Cancers|January 14, 2017
AR-Signaling in Human Malignancies: Prostate Cancer and BeyondMichael T Schweizer, Evan Y Yu
Expert Review of Molecular Diagnostics|September 26, 2007
Positron emission tomography imaging as a cancer biomarkerEvan Y Yu, David A Mankoff
Urologic Oncology|November 13, 2016
Making urothelial carcinomas less immune to immunotherapyJorge D Ramos, Evan Y Yu
Pageof 24